Navigation Links
Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
Date:11/12/2013

d delivered within the eye to maintain intraoperative mydriasis (pupil dilation), to reduce surgically induced miosis (pupil constriction), and to reduce postoperative pain and irritation. Maintenance of mydriasis is critical to the safety and surgical ease of the procedure. Intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "wi
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Omeros Corporation Reports Third Quarter 2013 Financial Results
2. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
3. Omeros to Present at the 12th Annual Needham Healthcare Conference
4. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
5. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
6. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
7. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
8. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
9. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
10. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
11. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 The new , ... , available today on PharmaBoardroom.com for ... crisis that rocked the Spanish economy in 2009, and the ... community has remained pragmatic in times of trouble. ... the fifth biggest European market, and the general conditions to ...
(Date:9/18/2014)... 2014 HealthTronics, Inc ., ... radiology products and services, announced that a poster ... cryoablation) versus external beam radiotherapy (EBRT) is being ... Urological Association (MAAUA) Annual Meeting in Baltimore, Maryland ... of Cryosurgery and External Beam Radiation as Treatments ...
(Date:9/18/2014)... 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research ... and "2014 Deep Research Report on Global and ... database. Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... Global and China Acetic Acid Industry" is a ... China and Global Acetic Acid Market. ...
(Date:9/18/2014)... Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), ... algae bioactive compounds and metabolic processes, is pleased to announce ... of directors. Ms. Nola E. Masterson , a ... the board effective September 17, 2014. "We,re ... join our board," states Andrew Dahl , President and ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... 10, 2009, NeoStem, Inc. (NYSE Alternext US: NBS) (the ... "Alternext") indicating that the Company is not in compliance ... "Guide"), which requires a listed company to hold meetings ... Company had announced that it planned to hold a ...
... ITMN ) today announced the pricing of an underwritten ... The last reported sale price of InterMune,s common stock on ... $17.96. The offering is expected to close on or ... All of the shares are being sold by the company.UBS ...
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today reported financial ... net loss for the second quarter of fiscal 2009,was $4.8 ... of $5.9 million,or $0.23 per share, in the second quarter ... expenses were $4.9 million in the second quarter of fiscal,2009, ...
Cached Biology Technology:NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 3Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 4Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 5Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 6Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 7
(Date:9/21/2014)... warming, are set to rise again in 2014 - reaching ... per cent projected rise in burning fossil fuels is revealed ... UK by researchers at the Tyndall Centre for Climate Change ... of Engineering, Mathematics and Physical Sciences at the University of ... Summit, where world leaders will seek to catalyse action on ...
(Date:9/21/2014)... California, San Diego, have developed a program that predicts ... of genes based on sequences of DNA. They describe ... human embryonic cells in a paper published in ... our cells have the same blueprint, the same DNA, ... author of the report. "Skin cells protect, nerve cells ...
(Date:9/21/2014)... strains of bacteria have emerged that resist even the ... forms of tuberculosis and staphylococcus, infect more than 2 ... the urgent need for new treatments, scientists have discovered ... decade. , MIT engineers have now turned a powerful ... that can disable any target gene, they have shown ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Program predicts placement of chemical tags that control gene activity 2Battling superbugs 2Battling superbugs 3Battling superbugs 4
... from ESA,s Envisat satellite radar are being used to ... Globe solo round-the-world yacht race. CLS, a subsidiary ... new radar applications division (formerly the BOOST Technologies Company), ... Envisat radar imagery to operationally observe oceans at high ...
... seascape that cleaves earlier each springthey may find relief in ... changes in the timing of sea-ice breakup and of snow ... least some polar bears with an alternative source of food. ... "Over 40 years, six subadult male bears were seen among ...
... battle against invading bacteria reaches its peak activity at ... Experiments with the laboratory model organism, Drosophila melanogaster, reveal ... with the body,s circadian rhythm, according to Stanford researchers ... Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 ...
Cached Biology News:Vendee Globe route seen from above 2Goose eggs may help polar bears weather climate change 2Immunity stronger at night than during day 2